Retraction: Metabolic remodeling precedes mitochondrial outer membrane permeabilization in human glioma xenograft cells (International Journal of Oncology (2012) 40 (509-518) DOI: 10.3892/ijo.2011.1255);Metabolic remodeling precedes mitochondrial outer membrane permeabilization in human glioma xenograft cells

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 509-518

  Ponnala, Shivani ^a   Chetty, Chandramu ^a   Veeravalli, Krishna Kumar ^a   Dinh, Dzung H ^a   Klopfenstein, Jeffrey D ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Aerobic glycolysis; Apoptosis; BAX; Bcl 2 protein family; Cathepsin B; Cytochrome c; MMP 9; Oxidative phosphorylation; Reactive oxygen species; uPAR

Indexed keywords

CATHEPSIN B; CYTOCHROME C; GELATINASE B; HEXOKINASE; HEXOKINASE 2; OLIGOMYCIN; PHOSPHOTRANSFERASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VOLTAGE DEPENDENT ANION CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN MITOCHONDRION; CELL MEMBRANE PERMEABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOSOL; GENE OVEREXPRESSION; GLIOMA; GLIOMA CELL; GLYCOLYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION; MOUSE; NONHUMAN; OUTER MEMBRANE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84855692830     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/IJO.2021.5198     Document Type: Erratum

References (65)

1. Baggetto LG: Deviant energetic metabolism of glycolytic cancer cells. Biochimie 74: 959-974, 1992.
2. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA and Dang CV: Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275: 21797-21800, 2000. (Pubitemid 30621745)
3. Pedersen PL: Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 22: 190-274, 1978.
4. Shim H, Chun YS, Lewis BC and Dang CV: A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 95: 1511-1516, 1998. (Pubitemid 28103423)
5. lalunis-Turner MJ, Franko AJ and Parliament MB: Modulation of oxygen consumption rate and vascular endothelial growth factor mRNA expression in human malignant glioma cells by hypoxia. Br J Cancer 80: 104-109, 1999.
6. Franko AJ, Parliament MB, lalunis-Turner MJ and Wolokoff BG: Variable presence of hypoxia in M006 human glioma spheroids and in spheroids and xenografts of clonally derived sublines. Br J Cancer 78: 1261-1268, 1998. (Pubitemid 28495235)
7. Kaanders JH and van der Kogel AJ: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 363: 78-79, 2004.
8. Vaupel P: Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198-206, 2004.
9. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713, 2008.
10. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007. (Pubitemid 46962095)
11. Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, Ligon KL, Rowitch DH and Louis DN: Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol 64: 948-955, 2005. (Pubitemid 41668924)
12. Wolf A, Agnihotri S and Guha A: Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 1: 552-562, 2010.
13. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL and Mischel PS: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024, 2005. (Pubitemid 41609094)
14. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB and Hay N: Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16: 819-830, 2004. (Pubitemid 39586539)
15. Pastorino JG, Shulga N and Hoek JB: Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 277: 7610-7618, 2002. (Pubitemid 34953160)
16. Dellagiacoma G, Sbarbati A, Rossi M, Zancanaro C, Benati D, Merigo F, Baldassarri A and Boicelli A: Brown adipose tissue: magnetic resonance imaging and ultrastructural studies after transplantation in syngeneic rats. Transplant Proc 24: 2986, 1992. (Pubitemid 23011792)
17. Singh KK: Mitochondrial DNA mutations. In: Aging, Disease and Cancer. Springer, New York, NY, 1998.
18. Chen LB: Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4: 155-181, 1988.
19. Kroemer G, Galluzzi L and Brenner C: Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99-163, 2007. (Pubitemid 46209992)
20. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ and Shore GC: Regulated targeting of BAX to mitochondria. J Cell Biol 143: 207-215, 1998. (Pubitemid 28480529)
21. Susin SA, Zamzami N and Kroemer G: Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1366: 151-165, 1998. (Pubitemid 28467029)
22. Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899, 2004. (Pubitemid 39472955)
23. Swietach P, Vaughan-Jones RD and Harris AL: Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26: 299-310, 2007. (Pubitemid 47101667)
24. Van Waveren C, Sun Y, Cheung HS and Moraes CT: Oxidative phosphorylation dysfunction modulates expression of extracellular matrix-remodeling genes and invasion. Carcinogenesis 27: 409-418, 2006. (Pubitemid 43372870)
25. Svineng G, Ravuri C, Rikardsen O, Huseby NE and Winberg JO: The role of reactive oxygen species in integrin and matrix metalloproteinase expression and function. Connect. Tissue Res 49: 197-202, 2008.
26. Kumar B, Koul S, Khandrika L, Meacham RB and Koul HK: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68: 1777-1785, 2008. (Pubitemid 351416563)
27. Nelson KK and Melendez JA: Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 37: 768-784, 2004. (Pubitemid 39078549)
28. Chetty C, Lakka SS, Bhoopathi P, Gondi CS, Veeravalli KK, Fassett D, Klopfenstein JD, Dinh DH, Gujrati M and Rao JS: Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Mol Cancer Ther 9: 2605-2617, 2010.
29. Veeravalli KK, Chetty C, Ponnala S, Gondi CS, Lakka SS, Fassett D, Klopfenstein JD, Dinh DH, Gujrati M and Rao JS: MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice. PLoS One 5: e11583, 2010.
30. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA and James CD: Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neurooncology 7: 164-176, 2005. (Pubitemid 40590516)
31. Gordan JD and Simon MC: Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 17: 71-77, 2007. (Pubitemid 46109295)
32. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
33. Tomiyama A, Serizawa S, Tachibana K, Sakurada K, Samejima H, Kuchino Y and Kitanaka C: Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 98: 1462-1473, 2006. (Pubitemid 44605591)
34. Tabatabaei P, Bergstrom P, Henriksson R and Bergenheim AT: Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy. J Neurooncol 90: 35-39, 2008.
35. Simon DK and O'Leary DD: Relationship of retinotopic ordering of axons in the optic pathway to the formation of visual maps in central targets. J Comp Neurol 307: 393-404, 1991.
36. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL and Thompson CB: The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173, 2005. (Pubitemid 40961771)
37. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM and Thompson CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899, 2004. (Pubitemid 38697301)
38. Pedersen PL, Mathupala S, Rempel A, Geschwind JF and Ko YH: Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555: 14-20, 2002. (Pubitemid 35245999)
39. Wolf A, Agnihotri S, Munoz D and Guha A: Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol Dis 44: 84-91, 2011.
40. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB and Hay N: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15: 1406-1418, 2001. (Pubitemid 32524647)
41. Lowry OH, Berger SJ, Carter JG, Chi MM, Manchester JK, Knor J and Pusateri ME: Diversity of metabolic patterns in human brain tumors: enzymes of energy metabolism and related metabolites and cofactors. J Neurochem 41: 994-1010, 1983. (Pubitemid 13018237)
42. Marzatico F, Curti D, Dagani F, Silvani V, Gaetani P, Butti G and Knerich R: Enzymes related to energy metabolism in human gliomas. J Neurosurg Sci 30: 129-132, 1986.
43. Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, Magdelenat H, Dutrillaux B and Poupon MF: Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 62: 216-222, 1995.
44. Azad MB, Chen Y and Gibson SB: Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 11: 777-790, 2009.
45. Simon HU, Haj-Yehia A and Levi-Schaffer F: Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5: 415-418, 2000. (Pubitemid 32162623)
46. Wochna A, Niemczyk E, Kurono C, Masaoka M, Kedzior J, Slominska E, Lipinski M and Wakabayashi T: A possible role of oxidative stress in the switch mechanism of the cell death mode from apoptosis to necrosis-studies on rho0 cells. Mitochondrion 7: 119-124, 2007. (Pubitemid 46351960)
47. Ahmad A, Ahmad S, Schneider BK, Allen CB, Chang LY and White CW: Elevated expression of hexokinase II protects human lung epithelial-like A549 cells against oxidative injury. Am J Physiol Lung Cell Mol Physiol 283: L573-L584, 2002.
48. Brand KA and Hermfisse U: Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J 11: 388-395, 1997. (Pubitemid 27193945)
49. Kim JW, Tchernyshyov I, Semenza GL and Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185, 2006.
50. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV and Semenza GL: HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407-420, 2007. (Pubitemid 46670080)
51. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998. (Pubitemid 28406816)
52. Shchepina LA, Pletjushkina OY, Avetisyan AV, Bakeeva LE, Fetisova EK, Izyumov DS, Saprunova VB, Vyssokikh MY, Chernyak BV and Skulachev VP: Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis. Oncogene 21: 8149-8157, 2002. (Pubitemid 35454417)
53. Matsuyama S, Xu Q, Velours J and Reed JC: The mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell 1: 327-336, 1998. (Pubitemid 128378881)
54. Eguchi Y, Shimizu S and Tsujimoto Y: Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57: 1835-1840, 1997. (Pubitemid 27209706)
55. Goldstein JC, Waterhouse NJ, Juin P, Evan GI and Green DR: The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2: 156-162, 2000.
56. Ikemoto H, Tani E, Ozaki I, Kitagawa H and Arita N: Calphostin C-mediated translocation and integration of Bax into mitochondria induces cytochrome c release before mitochondrial dysfunction. Cell Death Differ 7: 511-520, 2000. (Pubitemid 30303606)
57. Leist M, Single B, Castoldi AF, Kuhnle S and Nicotera P: Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185: 1481-1486, 1997. (Pubitemid 27187604)
58. Azoulay-Zohar H, Israelson A, bu-Hamad S and Shoshan-Barmatz V: In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 377: 347-355, 2004. (Pubitemid 38142190)
59. Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007. (Pubitemid 46328466)
60. Alexander HK, Booy EP, Xiao W, Ezzati P, Baust H and Los M: Selected technologies to control genes and their products for experimental and clinical purposes. Arch Immunol Ther Exp (Warsz.) 55: 139-149, 2007. (Pubitemid 46957404)
61. Antignani A and Youle RJ: How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane? Curr Opin Cell Biol 18: 685-689, 2006. (Pubitemid 44692478)
62. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001. (Pubitemid 32385543)
63. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB and Korsmeyer SJ: tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 14: 2060-2071, 2000. (Pubitemid 30637355)
64. Agostinelli E and Seiler N: Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids 31: 341-355, 2006. (Pubitemid 44537062)
65. Hamanaka RB and Chandel NS: Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci 35: 505-513, 2010.